GlassScriptPhysician profile
Rodel U Banal
NPI 1932422433
$7,291.84
in general payments reported to CMS, 2019-2025
27 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $363 · 2021: $164 · 2022: $229 · 2023: $5,182 · 2024: $552 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $1,717 · Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $1,716.73 |
| Food and Beverage | $1,638.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,906.29 | 2023 | Ion, Da Vinci Surgical System |
| Pulmonx Corporation | $1,169.67 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Actelion Pharmaceuticals US, INC. | $676.34 | 2022-2025 | Opsumit, Uptravi |
| Veran Medical Technologies, INC. | $282.73 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.11 | 2019-2025 | Ofev, Jascayd |
| Philips North America LLC | $123.78 | 2022-2024 | (Ak6) Vest Therapy |
| Insmed, INC. | $115.97 | 2020-2025 | Brinsupri, Arikayce |
| Glaxosmithkline, LLC. | $98.70 | 2020-2025 | Nucala |
| Olympus America INC. | $85.56 | 2021 | |
| Abiomed | $66.22 | 2025 | |
| Penumbra, INC. | $65.18 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $64.38 | 2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $56.39 | 2024 | |
| Electromed, INC. | $52.93 | 2025 | Smartvest |
| Harmony Biosciences LLC | $48.96 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $44.04 | 2019-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $37.84 | 2019 | |
| Inogen, INC. | $31.49 | 2022-2025 | |
| Verona Pharma, INC. | $31.14 | 2025 | Ohtuvayre |
| Fisher & Paykel Healthcare INC | $29.68 | 2021 | |
| United Therapeutics Corporation | $29.57 | 2025 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $22.52 | 2025 | Glassia |
| Resmed Corp | $21.72 | 2023 | |
| Grifols USA, LLC | $21.49 | 2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $18.04 | 2020 | |
| Mallinckrodt Hospital Products INC. | $17.40 | 2025 | Acthar |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodel Banal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.